Advertisement

A Filter Retardation Assay Facilitates the Detection and Quantification of Heat-Stable, Amyloidogenic Mutant Huntingtin Aggregates in Complex Biosamples

  • Anne Ast
  • Franziska Schindler
  • Alexander Buntru
  • Sigrid Schnoegl
  • Erich E. WankerEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1780)

Abstract

N-terminal mutant huntingtin (mHTT) fragments with pathogenic polyglutamine (polyQ) tracts spontaneously form stable, amyloidogenic protein aggregates with a fibrillar morphology. Such structures are detectable in brains of Huntington’s disease (HD) patients and various model organisms, suggesting that they play a critical role in pathogenesis. Heat-stable, fibrillar mHTT aggregates can be detected and quantified in cells and tissues using a denaturing filter retardation assay (FRA). Here, we describe step-by-step protocols and experimental procedures for the investigation of mHTT aggregates in complex biosamples using FRAs. The methods are illustrated with examples from studies in cellular, transgenic fly, and mouse models of HD, but can be adapted for any disease-relevant protein with amyloidogenic polyQ tracts.

Keywords

Filter retardation assay Protein misfolding Protein aggregation Coaggregation Insoluble aggregates Amyloidogenesis Seeding and spreading of protein aggregates 

Notes

Acknowledgment

This study received funding from the EC funding initiative ERA-NET NEURON, consortium “ABETA ID” funded by the German Federal Ministry for Education and Research (BMBF), grant no. 01W1301, the Berlin Institute of Health Collaborative Research Grant no. 1.1.2.a.3 “Elucidating the proteostasis network to control Alzheimer’s disease” funded by the German Federal Ministry for Education and Research (BMBF), the Helmholtz Validation Fund grant no. HVF-0013 “Enabling Technologies for Drug Discovery against Protein Misfolding Diseases” funded by the Helmholtz Association, Germany, (to E.E.W.), and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association for application-oriented research (to E.E.W.). Anne Ast and Franziska Schindler contributed equally to this work.

References

  1. 1.
    Becher MW, Kotzuk JA, Sharp AH et al (1998) Intranuclear neuronal inclusions in Huntington’s disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 397:387–397CrossRefGoogle Scholar
  2. 2.
    Huntington T, Macdonald ME, Ambrose CM et al (1993) A novel gene containing a trinucleotide that is expanded and unstable on huntington’s disease chromosomes. Cell 72:971–983CrossRefGoogle Scholar
  3. 3.
    Davies SW, Turmaine M, Cozens BA et al (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537–548CrossRefPubMedGoogle Scholar
  4. 4.
    Scherzinger E, Lurz R, Turmaine M et al (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90:549–558CrossRefPubMedGoogle Scholar
  5. 5.
    Harjes P, Wanker EE (2003) The hunt for huntingtin function: interaction partners tell many different stories. Trend Biochem Sci 28:425–433CrossRefPubMedGoogle Scholar
  6. 6.
    Chen S, Ferrone FA, Wetzel R (2002) Huntington’s disease age-of-onset linked to polyglutamine aggregation nucleation. Proc Natl Acad Sci U S A 99:11884–11889CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Difiglia M, Sapp E, Chase KO et al (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990–1993CrossRefPubMedGoogle Scholar
  8. 8.
    Scherzinger E, Sittler A, Schweiger K et al (1999) Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc Natl Acad Sci U S A 96:4604–4609CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Waelter S, Boeddrich A, Lurz R et al (2001) Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 12:1393–1407CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat Med 10:S10–S17CrossRefPubMedGoogle Scholar
  11. 11.
    Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501:45–51CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Falk HR, Comenzo LR, Skinner M (1997) The systemic amyloidosis. N Engl J Med 337:898–909CrossRefPubMedGoogle Scholar
  13. 13.
    Howie AJ, Brewer DB, Howell D et al (2008) Physical basis of colors seen in Congo red-stained amyloid in polarized light. Lab Investig 88:232–242CrossRefPubMedGoogle Scholar
  14. 14.
    Pecho-vrieseling E, Rieker C, Fuchs S et al (2014) Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons. Nat Neurosci 17:1064–1072CrossRefPubMedGoogle Scholar
  15. 15.
    Sieradzan KA, Mechan AO, Jones L et al (1999) Huntington’s disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol 99:92–99CrossRefGoogle Scholar
  16. 16.
    Steffan JS, Kazantsev A, Spasic-boskovic O et al (2000) The Huntington’s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 97:6763–6768CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    WMC v R-m, Reid SJ, Jones AL et al (2002) Insoluble TATA-binding protein accumulation in Huntington’s disease cortex. Brain Res Mol Brain Res 109:1–10CrossRefGoogle Scholar
  18. 18.
    Legleiter J, Mitchell E, Lotz GP et al (2010) Mutant Huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J Biol Chem 285:14777–14790CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Brundin P, Melki R, Kopito R (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 11:301–307CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Pearce MMP, Spartz EJ, Hong W et al (2015) Prion-like transmission of neuronal huntingtin aggregates to phagocytic glia in the Drosophila brain. Nat Commun 6:1–11CrossRefGoogle Scholar
  21. 21.
    Babcock DT, Ganetzky B (2015) Transcellular spreading of huntingtin aggregates in the Drosophila brain. Proc Natl Acad Sci U S A 112(39):E5427–E5433CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Wanker EE, Scherzinger E, Heiser V et al (1999) Membrane filter assay for detection of amyloid-like polyglutamine-containing protein aggregates. Methods Enzymol 309:375–386CrossRefPubMedGoogle Scholar
  23. 23.
    Kakkar V, Ma C, De Mattos EP et al (2016) The S/T-rich motif in the DNAJB6 chaperone delays polyglutamine aggregation and the onset of disease in a mouse model article the S/T-rich motif in the DNAJB6 chaperone delays polyglutamine aggregation and the onset of disease in a mouse model. Mol Cell 62:272–283CrossRefPubMedGoogle Scholar
  24. 24.
    Ehrnhoefer DE, Duennwald M, Markovic P et al (2006) Green tea (−)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington’s disease models. Hum Mol Genet 15:2743–2751CrossRefPubMedGoogle Scholar
  25. 25.
    Zurawel AA, Kabeche R, Digregorio SE et al (2016) CAG expansions are genetically stable and form nontoxic aggregates in cells lacking endogenous polyglutamine proteins. MBio 7:1–11CrossRefGoogle Scholar
  26. 26.
    Muchowski PJ, Schaffar G, Sittler A et al (2000) Hsp70 and Hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci U S A 97:7841–7846CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Cohen A, Ross L, Nachman I et al (2012) Aggregation of polyQ proteins is increased upon yeast aging and affected by Sir2 and Hsf1: novel quantitative biochemical and microscopic assays. PLoS One 7:1–10Google Scholar
  28. 28.
    Melkani GC, Trujillo AS, Ramos R et al (2013) Huntington’s disease induced cardiac amyloidosis is reversed by modulating protein folding and oxidative stress pathways in the Drosophila heart. PLoS Genet 9:e1004024CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kim YE, Hosp F, Frottin F et al (2016) Soluble oligomers of polyq-expanded huntingtin target a multiplicity of key cellular factors. Mol Cell 63:951–964CrossRefPubMedGoogle Scholar
  30. 30.
    Heiser V, Scherzinger E, Boeddrich A et al (2000) Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington’s disease therapy. Proc Natl Acad Sci U S A 97:6739–6744CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Heiser V, Engemann S, Bröcker W et al (2002) Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington’s disease by using an automated filter retardation assay. Proc Natl Acad Sci U S A 99:16400–16406CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Anne Ast
    • 1
  • Franziska Schindler
    • 1
  • Alexander Buntru
    • 1
  • Sigrid Schnoegl
    • 1
  • Erich E. Wanker
    • 1
    Email author
  1. 1.NeuroproteomicsMax Delbrueck Center for Molecular MedicineBerlinGermany

Personalised recommendations